Hemosol B0

Hemosol B0 is an electrolyte solution for haemodialysis that contains calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. Formulated as a sterile solution for injection, it is supplied in the European market under prescription status. The product provides essential electrolytes and buffering capacity to support acid‑base balance during renal replacement therapy and intravenous fluid administration. It is intended for use by healthcare professionals in controlled clinical settings.

Hemosol B0 is indicated for patients requiring renal replacement therapy or intravenous fluid replacement where electrolyte balance must be maintained. It is commonly employed during haemodialysis sessions and in acute care settings.

- Replacement of calcium, magnesium, sodium, and chloride losses that occur during dialysis. - Provision of bicarbonate precursors (hydrogen carbonate) to help correct metabolic acidosis. - Support of intravascular volume through isotonic fluid administration. - Compatibility with standard haemodialysis machines and tubing sets. - Use as a supplemental electrolyte source in patients receiving large-volume intravenous therapy.

Adverse reactions to Hemosol B0 are generally infrequent, but they may be reported in patients receiving the solution.

Common: - Mild transient nausea or vomiting. - Slight increase in serum calcium or magnesium levels. - Local irritation at the infusion site. - Mild headache.

Serious: - Severe hypercalcemia or hypermagnesemia. - Acute pulmonary edema from fluid overload. - Anaphylactic reaction or severe hypersensitivity.

Prior to administration, clinicians should evaluate patient-specific factors and monitor relevant laboratory parameters to minimize risk. Special attention is required for individuals with cardiac, hepatic, or renal impairment.

- Verify electrolyte concentrations and acid‑base status before infusion. - Adjust infusion rate in patients with compromised cardiac function. - Avoid use in uncontrolled hypercalcemia or hypermagnesemia. - Monitor fluid balance and weight to prevent overload. - Reassess serum electrolytes and bicarbonate after the procedure. - Consider contraindications in patients with known hypersensitivity to any component.

Hemosol B0 may interact with other intravenous medications or agents that affect electrolyte and fluid balance. Clinicians should review concurrent therapies to avoid additive effects.

Avoid: - Concurrent administration of calcium‑containing blood products without adjusting the solution’s calcium content. - Use with high‑dose magnesium supplements in patients prone to hypermagnesemia. - Simultaneous infusion of large volumes of other isotonic crystalloids that could cause fluid overload.

Use with caution: - Co‑administration with diuretics that may rapidly alter electrolyte levels; monitor closely. - Patients receiving ACE inhibitors or ARBs, as shifts in potassium and sodium may be amplified. - Anticoagulants used during haemodialysis; ensure compatibility with the infusion set.